Cyclooxygenase (COX), or prostaglandin (PG) H synthase, plays a role in inflammatory diseases, but very limited data exist on the regulation of COX in vivo. We, therefore, studied the in vivo expression of COX in synovia from patients with rheumatoid arthritis (RA) and osteoarthritis (OA), as well as joints of rats with streptococcal cell wall (SCW) and adjuvant arthritis. Extensive and intense intracellular COX immunostaining, which correlated with the extent and intensity ofmononuclear cell infiltration, was observed in cells throughout RA synovia. Significantly less or equivocal staining was noted in OA and normal human synovia. Similarly, COX immunostaining was equivocal in the joints of normal and arthritis-resistant F344/N rats. In contrast, high level expression developed rapidly in euthymic female Lewis (LEW/N) rats throughout the hindlimb joints and overlying tissues including skin, preceding or paralleling clinically apparent experimental arthritis. COX was expressed in the joints of athymic LEW.rnu/rnu rats 24 d after injection ofSCW or adjuvant but was not sustained. Physiological doses of antiinflammatory glucocorticoids, but not progesterone, suppressed both arthritis and COX expression in LEW/N rats. These observations suggest that, in vivo, (a) COX expression is upregulated in inflammatory joint diseases, (b) the level of expression is genetically controlled and is a biochemical correlate of disease severity, (c) sustained high level up-regulation is T cell dependent, and (d) expression is down-regulated by antiinflammatory glucocorticoids. (J. Clin. Invest. 1992. 89:97-108.)
Introduction
Exaggerated and dysregulated biosynthesis of prostaglandins (PGs), particularly PGE2, by synovial tissues is widely considered to play a role in the erosion of cartilage and juxtaarticular bone in rheumatoid arthritis (RA)' (1, 2) . Cyclooxygenase (COX), or PGH synthase (E.C. 1.14.99.1), the first enzyme of the pathway in which arachidonic acid is oxidized to PGs, is usually described as the rate-limiting step in PG production (3) . Use of COX inhibitors (nonsteroidal antiinflammatory drugs) in the treatment of RA is universal and further illustrates the perceived importance ofthis enzyme (4) . These drugs also have powerful antiinflammatory effects on experimental models of arthritis (5) . To understand the pathogenesis of inflammatory joint and other inflammatory diseases, mechanisms regulating the expression of this enzyme must be defined. Although the regulation of COX has been studied extensively in vitro (3), often with conflicting results, few studies have addressed the regulation of COX expression in vivo (6) . We have, therefore, studied the in vivo expression of COX in synovial tissues of patients with RA and osteoarthritis (OA) and in the joints of rats with streptococcal cell wall (SCW) and adjuvant arthritis (AA). Our data provide potentially important insights into the regulation of COX in vivo and its role in inflammatory joint diseases.
Methods
Human tissue specimens. Synovial specimens were obtained intraoperatively from the knees ofpatients with RA, OA, or a traumatic injury at time of arthroscopic biopsy or total joint replacement. All 19 patients with RA met the 1987 revised criteria for the classification of RA (7) . No attempt was made to segregate RA or OA patients on basis of duration of disease or clinically assessed disease activity. The specimens were preserved in 10% formalin, embedded in paraffin, and sec-cated SCW fragments in PBS, pH 7.4, was injected intraperitoneally into rats at a dose equivalent to 20 ,ug ofcell wall rhamnose per gram of body weight. This dose has been shown previously to induce acute and chronic polyarthritis in LEW/N female rats, and acute, but not chronic, polyarthritis in athymic nude LEW.rnu/rnu rats with 100% incidence. Relatively arthritis-resistant F344/N female rats were also injected. Rats injected with SCW (day 0) were killed in pairs at days 1-4 and 28, respectively. AA was induced in female LEW/N rats and clinically scored as described (10) . 200 ul of a suspension of pulverized Mycobacterium butyricum (Difco Laboratories, Inc., Detroit, MI) at 10 mg/ml in mineral oil (paraffin oil, heavy; Fisher Scientific Co., Pittsburgh, PA) were injected intradermally in 25-Mil aliquots in eight different locations, four on each side, ofthe cervical/periscapular region with a 25-gauge needle while the animals were under light anesthesia (day 0). Athymic LEW.rnu/rnu and arthritis-resistant F344/N rats, which do not develop clinically apparent AA, were also injected with the adjuvant suspension. Rats injected with adjuvant (day 0) were killed in pairs at 2-d intervals through the preclinical stages of disease until the development of maximal clinical arthritis (day 18). Hindfoot specimens were preserved in 10% formalin, decalcified in EDTA, embedded in paraffin, and sectioned (6 Beginning on the day of SCW (day 0) injection, the LEW/N rats were injected intraperitoneally with 1 ml of PBS containing 2% DMSO and progesterone (0.025 or 0.25 gg/g body weight, Sigma Chemical Co.) or dexamethasone (0.005, 0.025, or 0.05 ug/g body weight, Sigma Chemical Co.) twice a day. Control rats were injected with vehicle alone (PBS with 2% DMSO). Rats in each group were assessed for arthritis and killed at day 3. Tissues were processed for immunohistology and H & E staining as described above.
COX antibody preparation and characterization. Antiserum to ovine COX was produced in rabbits as previously described (12 [vol/vol] methanol) for 2 h at 400 mA as described (13) . The filter was blocked by incubation for 1 h in 50 mM Tris-HCl, pH 7.4 (TBS), containing 150 mM NaCl and 5% BSA. The blot was incubated with either 2 gg/ml ofanti-COX IgG or anti-COX IgG preincubated for 1 h with 50 ng ofpurified COX in TBS containing 5% BSA. After washing four times in TBS with 0.05% Triton X-100, the filter was incubated with alkaline phosphatase-conjugated anti-rabbit IgG and with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (Promega Biotec, Madison, WI) according to the manufacturer's instruction.
The specificity of the IgG anti-COX was further confirmed by absorption on purified ram seminal COX (Oxford Biomedical Research, Oxford, MI) coupled to cyanogen bromide-activated Sepharose 4B (Sigma Chemical Co.) (14) . COX antibody was added to the COXSepharose conjugate and incubated at room temperature for 2 h. The suspension was packed in a 0.7 X 4-cm column and washed with phosphate buffer (20 mM sodium phosphate, pH 7.3, with 0.5 M NaCi) until the OD2go returned to base line. The unbound IgG (affinity-negative) was devoid ofanti-COX activity. The antibody bound to the affinity column was eluted with thiocyanate buffer (3 M KSCN with 0.5 M ammonium hydroxide) and dialyzed against several changes of cold PBS. This affinity-purified IgG anti-COX was highly reactive in western blot analysis and immunohistochemistry (see below).
Immunohistochemistry. Immunoperoxidase staining with Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA) followed the manufacturer's suggested protocol (15) . All procedures were performed at room temperature. The sections were deparaffinized and endogenous peroxidase activity was exhausted by incubating in 0.3% peroxide in methanol for 45 min. The sections were preincubated with 0.1% BSA in PBS for 20 min and with diluted goat serum (1:66.7) for 20 min followed by incubation in a humid chamber with anti-COX antibody 50-75 ,g/ml, purified normal rabbit IgG (50- (17) .
Results
COX immunostaining on synovial tissues from patients with RA and OA. To study COX protein expression, we utilized the polyclonal antiserum raised against the purified ovine seminal vesicle COX (12) . The IgG fraction ofanti-COX antibody was used to immunohistochemically stain synovia from patients with RA and OA. Western blot analysis of the purified COX antibody confirmed that the COX antibody recognized the purified ovine COX (70 kD; lane I in Fig. 1 ). The reactivity of COX antibody was inhibited by preincubation ofthe antibody with purified COX (lane 2). As shown in a representative synovial tissue section, diffuse and intense intracellular staining was observed within the synovial lining cell layer (Fig. 2 , A and C). Prominent cytoplasmic COX staining was also observed in the sublining stromal fibroblast-like cells (Fig. 2 conjugate (Fig. 2 B) or nonspecific rabbit IgG (Fig. 2 F) was completely absent in all cases. Synovial tissue sections from patients with OA, in sharp contrast to the high-grade staining of RA specimens, stained weakly on the lining cell layer, sublining vascular endothelial cells and stromal fibroblast-like cells (Fig. 2 E) . Moreover, "normal" synovial tissue sections from a subject undergoing arthroscopy for suspected traumatic injury did not stain (data not shown).
Statistical analysis of COX immunostaining in vivo. The extent and intensity of synovial sublining cells stained with COX antibody were graded 0-4+ by a blinded observer on 19 RA and 12 OA synovial specimens. COX staining was significantly more extensive and intense in synovial specimens ofRA patients than on specimens ofOA patients (P < 0.01; Wilcoxon rank-sum test) as shown in Fig. 3 A. Moreover, there was a significant correlation (r = 0.76, P < 0.001; Spearman's rank correlation) between the extent and intensity of synovial sublining cells stained with COX antibody and the extent and intensity of mononuclear cell infiltration (assessed independently on H & E-stained sections) in synovia of RA patients (Fig. 3 B) . Only scattered, low intensity mononuclear cell infiltrates were seen in OA tissues.
COX immunostaining in SCW-injected euthymic LEW/N, athymic LEWrnu/rnu, and euthymic F344/N rats. Immunostaining of COX in the hindlimbs of SCW-injected euthymic LEW/N, athymic LEW.rnu/rnu rats, and arthritis-resistant F344/N female rats was studied at several time points. Within 24 h of SCW administration, euthymic LEW/N and athymic LEW.rnu/rnu rats, but not F344/N rats, developed erythema and swelling of peripheral joints as previously reported (18). Histologically, the acute inflammation, which reflects synovial microvascular injury, is characterized by edema, fibrin deposition in the joint space and synovium, and cellular infiltration by granulocytes and macrophages. This initial phase ofdisease reaches maximal severity at day 3 and substantially subsides over the next week (18). Expression of biochemical markers such as class II major histocompatibility complex (MHC) antigens (18), transin/stromelysin (19) and heparin binding (acidic fibroblast) growth factor-l, HBGF-l (16), is markedly increased during this initial phase of the experimental disease in euthymic LEW/N rats.
Basal expression of COX protein was absent or equivocal (Fig. 4 D, Table I ), but by day 1 after injection with SCW, low grade COX expression was readily demonstrated in the synovial lining cell layer, synovial stromal fibroblast-like cells, and perivascular inflammatory cells, paralleling the clinical disease.
By day 3 after SCW injection, the synovial lining cell layer, synovial stromal fibroblast-like cells and blood vessels, perivascular inflammatory cells, cartilage chondrocytes, and osteoblasts within bone matrix stained intensely (Table I ). The extent and intensity of staining was slightly higher in the euthymic LEW/N rats than athymic LEW.rnu/rnu rats at day 3 (Table I) antigens (18), transin/stromelysin (19) , and HBGF-I (16) has been noted. Histologically and radiologically apparent marginal erosions develop during this phase of the disease at the junctions of synovium with bone and cartilage and eventually the severely involved joints are destroyed (9, 19) . During the chronic phase, euthymic LEW/N (Fig. 4 , A-C), but not athymic LEW.mu/mu nor arthritis-resistant F344/N rats, intensely expressed COX in the cytoplasm of cells throughout the involved joints including the synovial-lining cell layer, subliming stromal cells (Fig. 4 A) , blood vessels (Fig. 4  B) , cartilage chondrocytes (Fig. 4 C) , and bone matrix cells as well as ligamentous and tendinous structures (Table I) (Fig. 4 F) , but not athymic LEW.rnu/rnu rats (Table I) , persistent COX expression in the skin was thymus-dependent like its expression in synovium, bone, and cartilage. In these rat strains the extent and intensity of COX expression in the skin paralleled COX expression in the joint lesions of SCW arthritis (Table I) . COX immunostaining in adjuvant-injected euthymic LEW/N, athymic LEW.rnu/rnu, and euthymic F344/N rats. The injection of a suspension of heat-killed mycobacteria in mineral oil induces chronic, destructive peripheral arthritis in LEW/N rats, but not athymic LEW.rnu/rnu rats, that appears clinically on or about day 10 after adjuvant injection (10, 20) . F344/N female rats developed equivocal or very low grade clinically apparent arthritis (data not shown). Clinically apparent arthritis in LEW/N rats is considered to be T cell mediated and may be passively transferred by lymphocytes (21, 22) . To determine when COX expression was first detected in AA, rats were killed at 2-d intervals after injection ofadjuvant and examined immunohistochemically.
Although basal expression ofCOX was absent or equivocal, low grade COX expression was readily demonstrated by day 4 after injection with adjuvant in synovial lining cell layer (Fig. 5 A), synovial stromal fibroblast-like cells (Fig. 5 A) , blood vessels (Fig. 5 A) , cartilage chondrocytes (Fig. 5 C) , subchondal bone, bone marrow cells, and skin epidermis (Fig. 5 E) in both LEW/ N and LEW.rnu/rnu rats without clinical or histologically apparent inflammation. Up-regulated COX expression was not noted in F344/N rats at any time point (Table II) . By days 10-18 after injection with adjuvant, COX was intensely expressed in synovial lining cell layer, synovial stromal fibroblastlike cells, blood vessels, cartilage chondrocytes, subchondral bone, bone marrow cells, and skin epidermis in euthymic LEW/N rats, but expression in LEW.rnu/rnu rats decreased to levels similar to controls (Table II) (Table  III) . Control staining with anti-COX antibody absorbed with COX-Sepharose conjugate or normal rabbit IgG was uniformly negative.
COX immunostaining in SCW-injected LEW/N rats treated with glucocorticoids or progesterone. Treatment of SCW-injected LEW/N rats with dexamethasone (1, 5, or 10 gg/d) strikingly suppressed clinical arthritis and COX expression in synovial lining cell layer (Fig. 6 D) , synovial stromal fibroblast-like cells (Fig. 6 D) , blood vessels (Fig. 6 D) , cartilage chondrocytes (Fig. 6 F) , subchondral bone, bone marrow cells, and skin epidermis (Fig. 6 H) in dose-dependent manner (Table IV). All SCW-injected control rats treated with vehicle alone or progesterone (5 or 50 ,g/d), a steroid without antiinflammatory activity, developed clinically and histologically acute, severe, SCW arthritis and high level COX expression (Table IV, Fig. 6 , A, C, E, and G). Control staining with anti-COX antibody absorbed with COX-Sepharose conjugate (Fig.  6 B) or normal rabbit IgG was uniformly negative. Additional control staining included anti-COX antibody plus dexamethasone (0.75, 7.5, or 75 jig/ml). The addition of dexamethasone to the antibody solution did not influence immunoreactivity, i.e., the results to the staining reaction were identical to Fig. 6 , A, C, E, and G. Discussion COX is the first enzyme of the pathway in which arachidonic acid is converted to PGs (3). COX is located in the endoplasmic reticulum and nuclear membrane but not in the plasma membrane or mitochondrial membrane of cultured fibroblasts (3, 23) . Increased COX enzyme activity is considered the critical factor in driving increased PG synthesis in an inflammatory site (3). Because rheumatoid synovial cells produce high levels of PGE2 that can accelerate bone resorption by osteoclasts (2) and because COX inhibitors (NSAIDs) are used extensively in the treatment ofRA and other inflammatory diseases (4) and effectively modulate various rat models of arthritis (5), study of COX regulation is important. Cytokines, such as interleukin 1 (IL-1) (24, 25), platelet-derived growth factor (PDGF) (25, 26) , transforming growth factor-# (TGF-f3) (27, 28) , epidermal growth factor (EGF) (29), HBGF-1 (16), and tumor necrosis factor (TNF) (30) have been implicated in the pathophysiology of RA, and the effects of some of these cytokines on COX expression on cells in vitro have been reported. For example, the stimulation of secreted PGE2 production by IL-1 was reported to correlate with an increase ofCOX protein in rheumatoid synovial cells in the absence of serum (31) . TGF-f3, on the other hand, increases COX mRNA in these cells and appears to synergize with IL-1 in increasing PGE2 production (32) . Simi increasing PGE2 production (33) . IL-I has also been reported to increase phospholipase A2 (PLA2) activity in rat synovial fibroblasts (34 Our data are also consistent with previous work on mechanisms determining the susceptibility and resistance of LEW/N and F344/N rats, respectively, to SCW arthritis (50, 51) and other inflammatory diseases including carrageenin-induced granuloma. F344/N female rats show a rapid and robust increase in plasma adrenocorticotropic hormone and corticosteroid levels, as well as increased hypothalamic release and synthesis ofcorticotropin releasing hormone, in response to SCW, IL-1, and many other stressful stimuli. This response is profoundly blunted and delayed in LEW/N rats. In present study, we found that glucocorticoids administered in physiologically relevant doses at the time of adjuvant and SCW injection suppressed both arthritis and COX expression in LEW/N rats in a dose-dependent manner. But progesterone, a steroid without antiinflammatory activity, did not suppress arthritis nor COX expression. We suspect, but did not formally prove, that increased plasma glucocorticoids may have down-regulated disease and COX synthesis in F344/N rats. Previously, we have showed that corticosteroid receptor antagonists precipitated severe, acute, SCW-induced inflammatory disease in this, otherwise, relatively resistant rat strain (50) . Although additional experiments are required, our data are consistent with the view that COX expression may be negatively regulated in vivo by glucocorticoids in physiologically relevant concentrations.
We have measured the mRNA levels for COX by using oligonucleotide primers designed against the human endothelial cell COX cDNA in the reverse transcriptase-polymerase chain reaction (35) . In contrast to the immunoreactive COX protein levels which showed a strong correlation with the disease phenotype, the mRNA levels for COX did not change in a similar manner (data not shown). Recent discovery of the second gene for COX (52, 53) as well as our own data (T. Hla, unpublished data) indicate that COX-I and COX-2 genes are expressed and regulated differentially in many cell types. Of Table IV . Day Sections from SCW-injected LEW/N rats treated with vehicle or dexamethasone and killed at day 3 were stained with anti-COX IgG (75 Ag/ml) as described in Methods. Positive staining importance, the polypeptide product of the COX-2 gene is highly homologous to COX-1 polypeptide (70% identity), suggesting that our polyclonal antibodies may cross-react with both forms of COX. Since the rat homologues of COX-1 and COX-2 cDNA have not been cloned, we cannot, at this point, determine the gene expression of COX-1 and COX-2 in SCWand adjuvant-induced arthritis models. Further studies, with gene-specific probes as well as isotype-specific antisera, will be necessary to determine the contribution ofCOX-I and COX-2 gene expression in inflammatory joint diseases.
The in vivo data that we have presented suggest that upregulated COX expression may be one of the earliest in vivo biochemical markers of the inflammatory cascade in RA in humans and SCW and AA in LEW/N rats. Up-regulated COX expression in vivo parallels the up-regulated expression ofclass II MHC antigens (18), transin/stromelysin (19, 54) , and HBGF-1 (16) , which are in vivo factors also implicated in these diseases. The data also suggest that the expression ofthese factors may be genetically controlled and mechanistically linked.
